OTC MARKETS · VAXX
+100.00% · +$0.0001 · Vol 227
Market closed · last close 4:00 PM ET · price as of 10:43:08 ET
Vaxxinity Inc

Vaxxinity Inc

Biotechnology
$0.0002
Card
Relationship Map

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D
Score not reportedVeridion does not publish a score-history trend for VAXX until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
AI Analysis
Sovereign

Why is VAXX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading VAXX catalysts
About Vaxxinity Inc
Biotechnology
Listed since
2021
Country
US

VAXXINITY INC A

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.0002
Day high
$0.0002
Day low
$0.0002
Previous close
$0.0001
52W high
$0.0440
-99.55% from high
52W low
$0.0001
0% of range
Market cap
$14.1K
EPS
$-0.4800
Beta
-30.31
Volume
227
0.02× rel vol
Avg volume
9.3K
VWAP
$0.0142
Price history computed in-house
1W
+100.00%
1M
+100.00%
3M
+100.00%
1Y
-99.33%
YTD
-33.33%
SMA 50 $0.0043 · below
SMA 200 $0.0045 · below
52W position 0%

VAXX overview

Loading financial statements
Loading VAXX Form 4 filings
Public disclosures

Congress activity in VAXX

No receipt-qualified Congressional disclosure is present for VAXX in the cached public ledger.

Federal contracts

VAXX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for VAXX in this window.
Lobbying spend

VAXX lobbying filings, year to date.

Registered lobbying filings matched to Vaxxinity Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for VAXX in this window.
Loading news for VAXX
Analyst ratings
Sovereign unlock shows live analyst consensus for VAXX.
Options
Sovereign unlock shows live options positioning for VAXX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.